CDGP — the most common cause of short stature and delayed puberty in otherwise healthy adolescents; a normal variant of maturational timing
Constitutional delay of growth and puberty (CDGP) is the single most common identifiable cause of both short stature and delayed puberty referred to pediatric endocrinology clinics. It describes children who are entirely healthy but whose skeletal maturation and reproductive axis simply switch on later than average — running a normal program on a slower clock, then catching up to reach a normal adult outcome.
CDGP typically declares itself early. Growth velocity is normal in infancy, but many affected children show a period of relative growth deceleration between roughly 6 months and 2-3 years of age as they settle onto a lower growth-curve channel — a phenomenon common to many constitutionally slow-maturing children. After this early "channel-crossing," linear growth resumes at a normal rate, but tracks along a curve that runs parallel to and below the population median, often near or just under the 3rd-5th percentile for chronological age.
Critically, growth VELOCITY is normal for bone age throughout mid-childhood — the child is growing at the expected rate for a younger, less skeletally mature child. This distinguishes CDGP from pathological growth failure, where velocity itself is subnormal even for bone age.
The clinical picture becomes most striking in early-to-mid adolescence. Around ages 11-14, peers enter the pubertal growth spurt — a 2-3 year window in which typically developing children gain 8-12 cm per year and rapidly develop secondary sexual characteristics. The CDGP adolescent, still prepubertal, does not experience this spurt yet, and the height gap versus classmates widens sharply during exactly the years when appearance and social comparison matter most.
Affected teens are the last in their peer group to show breast budding, testicular enlargement, growth of pubic/axillary hair, voice change, or a growth spurt. This gap is temporary: once the hypothalamic-pituitary-gonadal axis activates — later than average, but on the same trajectory the child’s biology always intended — the adolescent undergoes a delayed but otherwise normal puberty and growth spurt, closing most of the height gap with peers.
The defining natural-history feature of CDGP is that every developmental milestone is present and normal in sequence and character — only the timing is shifted later. Nothing is missing; nothing is out of order; it is simply running two or so years behind the average clock.
A detailed family history is often the single most useful diagnostic tool in the initial evaluation. Parents asked directly ("Were you a late bloomer? When did you get your growth spurt? When did you start shaving / have your first period?") will frequently recall being the shortest in their class through much of adolescence, entering puberty noticeably later than peers, and then undergoing a delayed but robust growth spurt in high school — sometimes into their late teens or even early twenties.
This recalled pattern is the parent’s own CDGP, and it is the strongest single predictor that the child in front of the clinician will follow the identical arc: prolonged childhood shortness, delayed but complete pubertal development, and a normal adult height and reproductive outcome.
CDGP is not a random developmental quirk — it clusters strongly in families and behaves, in many pedigrees, like an autosomal-dominant trait with variable penetrance and expressivity. Over the past decade, molecular genetics has begun to explain why: mutations in genes governing the developmental migration of GnRH-producing neurons can delay activation of the reproductive axis by years, while leaving every other aspect of development normal.
Multiple cohort studies converge on the same finding: somewhere between half and three-quarters of children and adolescents diagnosed with CDGP have at least one first-degree relative — most often a parent, sometimes a sibling — with a clearly recalled history of delayed puberty and/or a late adolescent growth spurt. Family pedigrees frequently show a pattern consistent with autosomal-dominant transmission with incomplete penetrance: an affected parent, an affected child, sometimes affected grandparents recalled retrospectively, and unaffected siblings who inherited the family’s average maturational timing rather than its delayed tail.
This heritability places CDGP within a broader biological spectrum: pubertal timing across the general population is itself a strongly heritable, polygenic trait, with twin studies estimating 50-80% of the variance in pubertal onset attributable to genetics. CDGP is best conceptualized as the extreme-but-still-normal tail of this same population distribution of maturational timing, rather than as a separate disease category.
In 2016, Howard and colleagues identified rare loss-of-function variants in IGSF10 (Immunoglobulin Superfamily Member 10) segregating with self-limited delayed puberty in several multi-generation families. IGSF10 is expressed in the nasal placode during early embryonic development, precisely where GnRH neurons originate before migrating along the terminal nerve to their eventual home in the hypothalamus.
Functional studies showed that IGSF10 knockdown delays the migration of GnRH neurons in cell and zebrafish models — the neurons still arrive at their destination and still eventually establish a functioning pulsatile GnRH-secreting network, but later than normal. This provides a compelling, mechanistically specific explanation for a phenotype that otherwise looked purely descriptive: a subset of CDGP is a disorder of neurodevelopmental TIMING in the reproductive axis, not a disorder of reproductive axis capability.
IGSF10 variants are found in only a minority of CDGP families (roughly 6-10% in published cohorts), underscoring that CDGP is genetically heterogeneous — many other as-yet-unidentified genes almost certainly contribute, consistent with its highly polygenic, population-level heritability.
Perhaps the most clinically important genetic insight of the last decade is that CDGP and idiopathic hypogonadotropic hypogonadism (IHH) — a permanent failure of GnRH secretion requiring lifelong hormone therapy — are not always cleanly separable at the genetic level. The same genes, including IGSF10 and several genes classically associated with IHH and Kallmann syndrome (e.g., FGFR1, GNRHR, TAC3/TACR3, among others), have been found to harbor rare variants in some CDGP pedigrees, and some families show both CDGP and IHH phenotypes among different members carrying related variants.
The emerging model is a spectrum, or "oligogenic" threshold, of GnRH-axis reserve: a variant load below a certain threshold produces self-limited delay (puberty is late but eventually happens spontaneously — CDGP), while a heavier variant load, or additional modifying mutations, produces a permanent failure to launch (IHH). This is an active area of research and has direct clinical relevance, because a small fraction of adolescents diagnosed with "probable CDGP" who do not spontaneously enter puberty by their late teens turn out to have IHH rather than simple delay — motivating ongoing follow-up rather than a one-time diagnosis and discharge.
CDGP remains fundamentally a clinical diagnosis of exclusion, but a consistent auxological and laboratory pattern strongly supports it and helps distinguish it from pathological causes of short stature or pubertal delay. The unifying theme across every test is concordance: bone age, height age, and hormone levels are all delayed together, by a similar margin, and are all appropriate for the child’s biological (bone) age rather than their chronological age.
A left-hand and wrist radiograph, scored against standardized atlases (Greulich-Pyle or Tanner-Whitehouse), estimates skeletal maturity independent of the calendar. In CDGP, bone age lags chronological age — commonly by 1.5-3 years at the time of typical presentation in early-to-mid adolescence — and this delay is the single best predictor of how much growing (and how much pubertal development) still remains.
Height age is calculated as the chronological age at which the child’s current height would sit at the 50th percentile. In CDGP, height age and bone age track closely together — a child who is skeletally 12 years old is also roughly the height of an average 12-year-old, even though they are chronologically 14. This concordance (bone age ≈ height age, both delayed versus chronological age) is the auxological hallmark that separates CDGP from most organic growth disorders, where height is frequently MORE delayed than bone age (or bone age is advanced, or discordant patterns emerge).
Basal or GnRH-stimulated LH and FSH in a CDGP adolescent are typically prepubertal — low, with a blunted LH response to stimulation — which mirrors what you would find in a healthy, normally developing child of the SAME BONE AGE. A chronologically 14-year-old with a bone age of 12 who has prepubertal gonadotropins is not abnormal; a 12-year-old (by skeletal maturity) with prepubertal gonadotropins is exactly what is expected.
Early morning basal LH, and particularly an LH rise after a GnRH or GnRH-agonist stimulation test, can also help distinguish CDGP from permanent hypogonadotropic hypogonadism: a measurable LH pulse or stimulated rise suggests the axis is present and simply not yet fully activated, favoring CDGP, whereas a flat, unresponsive axis in an older adolescent raises concern for IHH. In practice, this distinction can require longitudinal follow-up rather than a single test, since early CDGP and early IHH can look identical on a single stimulation test.
IGF-1 (and IGFBP-3) are growth-hormone-axis markers that rise with pubertal maturation. In CDGP, IGF-1 is low-normal FOR CHRONOLOGICAL AGE but appropriate FOR BONE AGE — again reflecting a normally functioning axis running on a delayed timetable, not a defective one.
The remainder of the work-up exists to actively exclude organic mimics before settling on CDGP as the diagnosis:
• Thyroid function (TSH, free T4): hypothyroidism causes growth failure and can delay puberty • Celiac screen (tTG-IgA) and inflammatory markers: occult malabsorptive or inflammatory disease can present as growth failure • Karyotype: particularly in girls with short stature, to exclude Turner syndrome; in boys with pubertal delay and disproportionate features, to consider Klinefelter syndrome • Prolactin, and pituitary/hypothalamic imaging (MRI) when indicated: to exclude a structural cause of hypogonadotropic hypogonadism, especially if anosmia, midline defects, visual field changes, or headache are present • Complete blood count, renal and hepatic panels: to screen for chronic systemic disease
Only once these are normal — and the auxological pattern of concordant, proportionate delay is present, ideally alongside a supportive family history — is CDGP confidently diagnosed.
No single laboratory test "rules in" CDGP. The diagnosis rests on a consistent gestalt — concordant bone-age/height-age delay, hormone levels appropriate for bone age, a supportive family history, and a normal work-up otherwise — combined, when needed, with longitudinal observation to confirm that puberty is indeed progressing rather than permanently absent.
CDGP is medically benign, but its social and psychological consequences during adolescence are real and should never be dismissed. Being visibly shorter, less muscular, and less sexually developed than peers during the exact years when social comparison, dating, sports team selection, and body image are most salient can produce genuine distress. For most adolescents with CDGP, the correct medical management is reassurance, education, and monitoring — but this must be delivered in a way that takes the psychosocial burden seriously rather than minimizing it.
Adolescents with CDGP are not just shorter on a growth chart — they are often mistaken for younger children by teachers, coaches, and strangers; excluded from competitive sports where size and strength matter (particularly contact sports for boys); the last in their friend group to be included in conversations about shaving, periods, dating, or physical changes; and sometimes targets of teasing or bullying, especially in locker rooms and gym classes where physical development is visible and compared.
Studies of adolescents with constitutional delay consistently find higher rates of poor body image, lower self-esteem, and greater social anxiety compared with on-time-maturing peers, particularly in boys — for whom height and visible pubertal markers (facial hair, voice change, muscle mass) carry outsized social currency in adolescent male peer hierarchies. Girls with CDGP report similar concerns around being perceived as immature or "left behind" by classmates who have already progressed through puberty.
The clinical rationale for reassurance-first management is not a minimization of the child’s distress — it is that the natural history of CDGP is so reliably favorable that intervention is usually unnecessary to achieve a normal outcome:
• Puberty WILL start spontaneously. By definition, in true CDGP the hypothalamic-pituitary-gonadal axis is intact and simply activates later; essentially all boys have entered puberty by bone age 13-14 (often chronological age 15-17), and all girls by a comparably delayed but bounded window • Catch-up growth WILL occur. Once puberty begins, the growth spurt follows the same pattern as any adolescent’s — often a robust, sometimes prolonged spurt that closes most or all of the apparent height deficit • Adult height is typically normal. Final adult height in CDGP generally falls within the child’s genetic target range (based on mid-parental height), because the delay affects TIMING of growth, not its ultimate TOTAL amount
Effective reassurance is active, not passive: explaining the mechanism in plain language ("your growth plates and reproductive system are simply on a slower alarm clock — everything is there and working, it just goes off later"), showing the child and family a bone-age X-ray alongside a growth curve, sharing the parent’s own recalled history as living proof of the expected trajectory, and scheduling concrete follow-up (typically every 6 months) so the family has a structured way to track visible progress rather than facing an open-ended wait.
Reassurance is a genuine, active medical intervention in CDGP — not merely the absence of treatment. Framing, evidence (bone age, family history), and scheduled follow-up meaningfully reduce anxiety and are considered appropriate first-line management by pediatric endocrine society guidelines for adolescents without severe psychosocial impairment.
Reassurance is sufficient for most adolescents with CDGP, but not all. Indications to consider moving beyond watchful waiting toward a more active intervention (see Stage 5) include: significant, persistent psychosocial distress despite counseling and education (poor school engagement, withdrawal from sports or social activities, depressive or anxious symptoms attributable to pubertal delay); bone age reaching a threshold (commonly cited as roughly 12 years in boys) with no signs of pubertal onset, raising both distress and diagnostic uncertainty; or explicit patient/family preference for a more active approach after a full discussion of risks, benefits, and alternatives.
Screening for distress should be routine at every follow-up visit — brief, direct questions about teasing, sports participation, mood, and self-image — rather than waiting for a crisis to surface. Many adolescents will not volunteer distress unprompted, particularly boys, for whom admitting difficulty with body image carries its own social stigma.
When psychosocial distress is significant, a brief, low-dose course of sex steroid therapy — testosterone in boys, estrogen in girls — can accelerate the visible onset of secondary sexual characteristics and a modest growth acceleration, without altering the eventual normal adult height or overriding the adolescent’s own endogenous pubertal trajectory. This is a well-established, time-limited bridge therapy, not a permanent hormone replacement — the child’s own axis resumes control once the course ends.
In boys, low-dose intramuscular testosterone esters (commonly 50-100 mg monthly for 3-6 months, well below adult replacement doses) are given to stimulate the physical changes of early puberty: growth of the penis and pubic hair, some voice deepening, a modest acceleration of linear growth velocity, and a boost in confidence and body image. In girls, low-dose oral or transdermal estrogen for a similarly brief course can stimulate early breast development and a modest growth acceleration.
The key pharmacologic principle is dose and duration: at these low doses and short durations, exogenous sex steroid does not meaningfully advance bone age or accelerate epiphyseal fusion, and it does not suppress the adolescent’s own hypothalamic-pituitary-gonadal axis into a persistent, medication-dependent state. The course functions as a visible "kick-start" — giving the body a preview of the changes that are coming anyway — while the adolescent’s own endogenous puberty, already primed by rising bone age, typically emerges spontaneously during or shortly after the treatment course and then carries the process to completion.
The reassuring evidence base behind this approach, built over several decades of pediatric endocrine practice and multiple long-term follow-up studies, is that adolescents treated with a short, low-dose course reach adult heights statistically indistinguishable from untreated CDGP adolescents and from their genetically predicted target height range (calculated from mid-parental height). Because the dose is deliberately kept below the threshold that meaningfully accelerates skeletal maturation, the "growing window" — the time remaining before growth plates fuse — is preserved rather than shortened.
Similarly, because the course is short and the dose low, it does not suppress or replace the adolescent’s own reproductive axis. Endogenous LH and FSH pulsatility, once it begins (often overlapping with or shortly following the treatment course, since the treated adolescent’s own bone age has by then advanced closer to the normal pubertal threshold), proceeds to drive full, complete, self-sustaining puberty — normal testicular growth and spermatogenesis in boys, normal ovarian function and menstrual cycles in girls — with no need for repeat or ongoing treatment.
The therapeutic goal of short-course sex steroid treatment in CDGP is explicitly psychosocial, not auxological: it exists to relieve the distress of being a visibly late developer during a socially high-stakes window, not to "fix" a growth or pubertal abnormality — because there is no abnormality to fix. Growth and pubertal potential were always normal; only the clock was slow.
Short-course therapy is reserved for adolescents who meet appropriate criteria: a confirmed diagnosis of CDGP (organic causes excluded), bone age typically in a range near the expected pubertal threshold (often cited as approximately 12 years or older in boys), and clinically significant psychosocial distress that has not resolved with reassurance and education alone.
Monitoring during and after treatment includes periodic bone age assessment (to confirm the treatment is not inappropriately accelerating skeletal maturation), growth velocity tracking, and clinical assessment of pubertal staging (Tanner staging) to document the transition from treatment-induced changes to the adolescent’s own endogenous, self-sustaining puberty. Family and patient should be counseled explicitly, before starting, that this is a temporary bridge — treatment is stopped after the planned course, and the expectation is that endogenous puberty will have begun or will begin shortly after, not that ongoing hormone therapy will be required.
Ultimately, the existence of this well-validated option underscores the core message of CDGP as a diagnosis: it is a variant of normal timing, with a normal endpoint, for which medicine offers both patience (reassurance, the default) and, when needed, a safe, time-limited tool to ease the adolescent through a temporarily difficult social window.